Latest Clinical trial Stories
NEW YORK, March 2, 2015 /PRNewswire/ -- Delcath Systems, Inc.
- Study reproduced earlier findings that a single, 2-hour intravenous administration of vepoloxamer resulted in robust improvements in key parameters of heart function that persisted for up to 2 weeks
TORONTO, March 2, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics
A New Drug Approved for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer WOODCLIFF LAKE, N.J.,
-Strengthened balance sheet enables focus on both Kanuma(TM) (sebelipase alfa) and multiple pipeline programs- LEXINGTON, Mass., Feb.
Live Webcast from Boston on March 4th SAN DIEGO, Feb. 26, 2015 /PRNewswire/ -- MEI Pharma, Inc.
BOSTON, Feb. 26, 2015 /PRNewswire/ -- Columbia Laboratories, Inc.
DALLAS, February 26, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Strongyloidiasis Global Clinical Trials Review, H2, 2014" market research report to its store.
BOSTON, February 25, 2015 /PRNewswire/ -- Smooth Drug Development [http://smoothdd.com/en ] announced gaining the internationally renowned ISO 9001:2008 certification [http://en.wikipedia.org/wiki/ISO_9000#Summary_of_ISO_9001:2008_in_informal_language
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.